Skip to main content
AstraZeneca PLC logo

AstraZeneca PLC — Investor Relations & Filings

Ticker · AZN ISIN · GB0009895292 LEI · PY6ZZQWO2IZFZC3IOL08 IL Manufacturing
Open in API
Filings indexed 3,411 across all filing types
Latest filing 2021-05-07 Merger & Acquisition
Country GB United Kingdom
Listing IL AZN

About AstraZeneca PLC

https://www.astrazeneca.com/

AstraZeneca PLC is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialization of prescription medicines. The company's portfolio is concentrated on several main therapy areas, including Oncology; Cardiovascular, Renal & Metabolism; and Respiratory & Immunology. AstraZeneca is committed to advancing healthcare through a robust research and development pipeline, aiming to deliver innovative medicines that address significant unmet medical needs for millions of patients worldwide. The company leverages scientific innovation to transform the future of healthcare and improve patient outcomes.

Recent filings

Filing Released Lang Actions
425 Filing
Merger & Acquisition Classification · 100% confidence The document is filed by AstraZeneca PLC pursuant to Rule 425 under the U.S. Securities Act of 1933, which is typically used for communications related to merger and acquisition transactions. The text references the proposed acquisition of Alexion Pharmaceuticals, including details about the registration statement on Form F-4, proxy statements/prospectuses, and solicitation of proxies. It also contains forward-looking statements related to the acquisition and integration risks. There is no actual financial data or detailed financial report content; rather, it is a communication about the acquisition process and related filings. The presence of Rule 425 and the focus on acquisition-related disclosures clearly indicate this is related to merger and acquisition activity. Therefore, the appropriate classification is Merger & Acquisition (MA).
2021-05-07 English
425 Filing
Merger & Acquisition Classification · 95% confidence The document is a communication filed pursuant to Rule 425 under the U.S. Securities Act of 1933, which is typically used for merger-related communications. It discusses transition planning, organizational structure, and operational updates related to AstraZeneca's proposed acquisition of Alexion Pharmaceuticals. It references the filing of a Form F-4 registration statement and a proxy statement/prospectus related to the acquisition. The content focuses on merger transaction updates and shareholder solicitation information rather than financial results, audit opinions, or regulatory certifications. The document is not a full financial report, earnings release, or proxy solicitation material itself but rather a communication providing updates on the merger process and transition plans. Given these characteristics, the document fits best under the category of Merger & Acquisition (MA) filings, specifically a Rule 425 communication related to the acquisition process.
2021-05-06 English
425 Filing
Merger & Acquisition Classification · 95% confidence The document is filed pursuant to Rule 425 under the U.S. Securities Act of 1933, which relates to communications in connection with a merger or acquisition. It references AstraZeneca's proposed acquisition of Alexion Pharmaceuticals and mentions the filing of a Form F-4 registration statement, which includes a proxy statement/prospectus related to the acquisition. The document contains a note from AstraZeneca's CFO discussing Alexion's quarterly results and the acquisition, but it does not itself contain detailed financial statements or a full report. Instead, it serves as a communication to employees and investors about the acquisition and related filings. The presence of Rule 425 and the focus on acquisition-related communications indicate this is a merger-related filing. Given the specific mention of Rule 425 and the nature of the content, the document fits best under the category of Merger & Acquisition (MA) filings, which include merger communications such as Form 425 filings. The document is not a full annual or quarterly report, proxy solicitation, or earnings release, but a communication related to the acquisition process.
2021-05-05 English
TOTAL VOTING RIGHTS
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a Form 6-K filed by AstraZeneca PLC, which is a report of a foreign issuer pursuant to the Securities Exchange Act of 1934. The content focuses on the total voting rights as of April 30, 2021, including the number of issued shares and voting rights. It references the UK Financial Conduct Authority's Disclosure and Transparency Rule 5.6.1, indicating it is a regulatory disclosure about voting rights and capital structure. The document is relatively short (3119 characters) and does not contain financial statements or detailed financial analysis. It is not an annual or interim report, nor an earnings release or management discussion. It is a regulatory announcement about voting rights, which fits the category of Declaration of Voting Results & Voting Rights Announcements (DVA).
2021-05-04 English
Total Voting Rights
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is identified by the RNS Number header and explicitly states it is a notification made in accordance with the UK Financial Conduct Authority's Disclosure and Transparency Rule 5.6.1. The content details the total number of voting rights and the issued share capital as of a specific date (April 30, 2021). This type of regulatory disclosure regarding voting rights and capital structure is a specific regulatory announcement. While it relates to capital, it is not a financing activity (CAP) or a share issue (SHA), but rather a mandatory disclosure of existing voting rights structure. This fits best under the general regulatory announcement category, RNS, as it is a standard regulatory filing disseminated via the RNS service.
2021-05-04 English
FARXIGA APPROVED IN THE US FOR CKD
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filing by AstraZeneca PLC, submitted pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934. It reports the approval of Farxiga in the US for chronic kidney disease (CKD) treatment, including detailed clinical trial results and background information. The document is a regulatory announcement of a significant corporate event (FDA approval of a drug) rather than a financial report, earnings release, or management discussion. It does not contain financial statements or detailed financial analysis. The Form 6-K is a report of foreign issuer events and is typically classified under Regulatory Filings (RNS) as it does not fit into other specific categories such as earnings release or investor presentation. The document length (13,446 characters) is substantial but the content is primarily a regulatory announcement about drug approval and clinical trial results, not a financial report or presentation. Therefore, the appropriate classification is Regulatory Filings (RNS).
2021-05-04 English

Browse filings by year

34 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.